Immunotherapy: T cells get a ride

Nature Reviews Cancer 17, 333 (2017). doi:10.1038/nrc.2017.39 Author: M. Teresa Villanueva Strategies that inhibit the immune checkpoint blockade (ICB) and reactivate T cells using monoclonal antibodies against programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1) have been used to successfully treat immunogenic tumours, and recent efforts have focused on combining this approach with
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Tags: Research Highlight Source Type: research